LCAR-B4822M is a CAR-T cell immunotherapy made from a patient's own peripheral blood mononuclear cells collected by leukapheresis and engineered to be given back by intravenous injection after lymphodepleting pre-treatment. It is studied in refractory or relapsed multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
At a glance
Drug type
Cell therapy (CAR-T)
Targets
B-cell maturation antigen (TNFRSF17) (antigen)
Mechanism
Kills target cells, directed at B-cell maturation antigen (TNFRSF17)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.